Teva Pharmaceutical Industries: (NYSE: TEVA)

$39.36

-0.28 (-0.71%)

Volume 225,626

Jun 19 10:04 AM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		39.16 - 39.72
	
		52wk Low - High
		36.63 - 42.83
	
		Previous Close
		39.64
	
		Avg. Volume
		3,632,639
	
		Industry
		MED-GENERIC DRG
	
		Market Cap
		33.97 B
	
		Div - Yield
		0.94 - 2.38
	
		Beta
		0.38
	
		P/E (F1)
		7.86
	
		Current Year Est.
		5.04
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		213 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/7/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            7.86
                        
                            PEG Ratio
                            1.04
                        
                            Current Year Est.
                            5.04
                        
                            Current Quarter Estimate
                            1.20
                        
                            Most Accurate Estimate
                            1.20
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            5.00
                        
                            Expected Earnings Growth
                            7.56%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals.  Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies.  The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions.  Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.   
Full TEVA Company Report

 Analyst Report on TEVA

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
TEVA Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.20	1.30	5.04	5.46
Number of Estimates	15	15	16	15
Low Estimate	1.04	1.27	4.86	4.86
High Estimate	1.32	1.33	5.17	NA
Year Ago EPS	1.28	1.28	5.35	5.04
EPS Growth	-6.15%	1.41%	-5.71%	8.32%

More TEVA Estimates

Average Earnings Estimates for TEVA

EPS Growth for TEVA

Industry Analysis

Name	Symbol	Previous Close
TEVA PHARM ADR	TEVA	39.64
ACTAVIS INC	ACT	125.67
ACURA PHARMACT	ACUR	2.13
HI TECH PHARMA	HITK	33.91
IMPAX LABORATRS	IPXL	18.85
KALOBIOS PHARMA	KBIO	5.08
MYLAN INC	MYL	31.87
OMTHERA PHARMA	OMTH	13.00
SIMCERE PHARMAC	SCR	9.48
SUPERNUS PHARMA	SUPN	6.67

Sector:Medical>> Industry:MED-GENERIC DRG

COMPARE TICKER vs. Its Peers

Zacks Commentary

Teva to Acquire MicroDose Therapeutx

Jun 18, 2013

$2.15B Settlement for Pfizer's Protonix

Jun 13, 2013

SGEN Starts Adcetris Phase I/II Study

Jun 11, 2013

The Zacks Analyst Blog Highlights: Eli Lilly, Teva, Salix Pharmaceuticals, Santarus and Turkcell Iletisim Hizmetleri

Jun 05, 2013

Eli Lilly's Alimta Disappoints

Jun 04, 2013

Shire Settles Lawsuit with Teva

Jun 03, 2013

CHMP Positive on Teva's Lonquex

Jun 03, 2013

FDA Accepts Teva sNDA

May 31, 2013

More TEVA Zacks Commentary

Financials

EPS TTM	5.00
Sales	20,317
Net Income	1,734
Price/Earnings	7.93
Price/Book	1.49
Price/Cash Flow	5.33
Price/Sales	1.69

More TEVA Financials

News

Benzinga`s Top Initiations - Benzinga

Jun 19, 2013

Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's - Pr Newswire

Jun 19, 2013

Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy`s - Benzinga

Jun 19, 2013

Teva to Present at the 2013 International Congress of Parkinson's Disease and Movement Disorders - Close-Up Media

Jun 19, 2013

Teva Pharmaceutical (TEVA) Showing Bullish Technicals But Could Break Through $39.71 Resistance - Freshbrewedmedia

Jun 18, 2013

Teva Pharmaceutical Industries Ltd to acquire MicroDose Therapeutx for USD40m at closing - M2

Jun 18, 2013

Teva Pharmaceutical to acquire 100% stake in MicroDose Therapeutx - Datamonitor Financial Deals Tracker

Jun 18, 2013

Teva Reports Azilect (Rasagiline Tablets) Data to Be Presented at the International Congress of Parkinson's Disease and Movement Disorders - Close-Up Media

Jun 18, 2013

See All News Stories on TEVA

Broker Recommendations

Current ABR	2.16
ABR (Last Week)	2.16
# of recs in ABR	25
Average Target Price	43.75
Industry Rank by ABR	213 out of 265
Rank in Industry	2 out of 14

More TEVA Broker Recommendations

Day Low - High	39.16 - 39.72
52wk Low - High	36.63 - 42.83
Previous Close	39.64
Avg. Volume	3,632,639
Industry	MED-GENERIC DRG
Market Cap	33.97 B
Div - Yield	0.94 - 2.38
Beta	0.38
P/E (F1)	7.86
Current Year Est.	5.04
Quarterly Earnings ESP	0.00%

P/E (F1)	7.86
PEG Ratio	1.04
Current Year Est.	5.04
Current Quarter Estimate	1.20
Most Accurate Estimate	1.20
Earnings ESP	0.00%
Next Earnings Report Date	08-08-2013
EPS Last Year	5.00
Expected Earnings Growth	7.56%

Username: Password:

Remember me [?]

Teva Pharmaceutical Industries: (NYSE: TEVA)

$39.36

-0.28 (-0.71%)

Volume 225,626

Jun 19 10:04 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-GENERIC DRG

Zacks Commentary

Financials

News

Broker Recommendations